Lucid Genomics
Lucid Genomics provides a platform for long-read genomics that transforms raw sequencing data into actionable insights for research, diagnostics, and drug discovery.
Classification
Profile
Funding
Funding details not yet available.
Transforms raw Long Read sequencing data into actionable insights for structural variants and repeat regions at scale for research, diagnostics, and drug discovery.
Research institutions, diagnostic laboratories, and pharmaceutical companies engaged in drug discovery requiring whole genome decoding.
SaaS platform licensing and usage-based pricing for genomic data analysis.
Direct sales, LinkedIn outreach, and website-driven lead generation.
Spin-off from [unspecified] academic/research institution.
Primarily driven by high-end bioinformatics R&D and the technical expertise required to develop and maintain the long-read analysis platform.
Proprietary 'Lucid' platform for variant detection and long-read analysis, and a multidisciplinary team of geneticists and bioinformaticians.
Developing the Lucid platform to bridge translational gaps from cutting-edge science to patient impact, focusing on structural variant and repeat region detection.
Sales-led with tailored solutions for enterprise clients and research collaborators.
Competes in the long-read genomics space by bridging the gap between cutting-edge science and patient impact, focusing on structural variants and repeat regions.
Difficulty decoding whole genomes from raw Long Read sequencing data, specifically lacking actionable insights on structural variants and repeat regions for diagnostics and research.
- Introduce a “Biomarker-Discovery” SaaS Add-On
- Target Market Focus: Do you intend to prioritize clinical diagnostics (CE-IVD) over research/academic use, or maintain a balanced portfol
Speed & Accuracy (Value) → Premium Pricing (Revenue) → Funding for R&D (Key Resources) · Academic Partnerships (Key Partnerships) → Credibility (Customer Relationships) → Faster Enterprise Sales (Channels) · API Marketplace (Channels) + Hybrid Edge Compute (Key Activities) → Lower Cloud Costs (Cost Structure) + Expanded SMB Reach (Customer Segmen
Funding Validation: Secured €1.3 M pre-seed round (Caesar Ventures, BIF Partners) in 2024, confirming investor confidence and runway for pro · Academic Partnerships: Active collaborations with Charité and Max Planck Institute provide peer-reviewed validation and a pipeline of early- · Performance Benchmarks: Independent testing shows 87 % false-pos
No investors recorded yet.